FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Amicus Therapeutics (FOLD) reported Q2 2025 adjusted EPS of $0.01, missing consensus estimates, though revenues increased 22% year-over-year to $154.7 million, surpassing expectations, primarily driven by Galafold and Pombiliti + Opfolda sales. Operating expenses rose significantly due to a $30 million upfront payment for the DMX-200 licensing agreement, a potential blockbuster for FSGS. Despite the EPS miss and a 36.4% year-to-date share decline, FOLD reaffirmed its 2025 revenue growth guidance of 15-22% and its target for GAAP profitability in the second half of 2025, with an aim to exceed $1 billion in total sales by 2028.

Analysis

Amicus Therapeutics reported mixed second-quarter 2025 results, characterized by a revenue beat but an earnings miss. Total revenues grew a robust 22% year-over-year to $154.7 million, exceeding consensus estimates of $148 million, driven by solid performance from its rare disease portfolio. However, adjusted earnings per share of $0.01 fell short of the $0.02 consensus estimate. The company's core product, Galafold, saw sales rise 12% at constant exchange rates to $128.9 million, yet this figure was below the $133 million analyst consensus, indicating a potential deceleration. This was offset by a strong launch for the Pombiliti + Opfolda combination therapy, which generated $25.8 million, surpassing expectations. A significant factor in the quarter was the 56% surge in adjusted operating expenses, primarily driven by a $30 million upfront payment to license Dimerix's DMX-200, a potential first-in-class treatment for the rare kidney disease FSGS. Despite the earnings miss and a significant 36.4% year-to-date decline in share price, management reaffirmed its full-year guidance, projecting 15-22% revenue growth and, critically, the achievement of GAAP profitability in the second half of 2025, signaling confidence in its operational trajectory and strategic investments.

Key Decisions for Investors

• Investors should closely monitor the sales trajectory of Pombiliti + Opfolda to ensure its strong ramp-up can offset the slight consensus miss from Galafold and validate the company's reaffirmed 15-22% revenue growth guidance.
• The strategic licensing of DMX-200 introduces a significant long-term catalyst; progress on its Phase III trial, expected to complete enrollment by year-end 2025, should be tracked as a key value driver.
• Given the stock's 36.4% underperformance year-to-date against a confident outlook for GAAP profitability in H2 2025, investors may see a valuation disconnect, but must weigh the potential reward against execution risks in both commercial sales and clinical development.